Cargando…
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 “tag-mutate-enrich” mutagenesis screens, we identify close to full-length mutant forms...
Autores principales: | Pettitt, Stephen J., Krastev, Dragomir B., Brandsma, Inger, Dréan, Amy, Song, Feifei, Aleksandrov, Radoslav, Harrell, Maria I., Menon, Malini, Brough, Rachel, Campbell, James, Frankum, Jessica, Ranes, Michael, Pemberton, Helen N., Rafiq, Rumana, Fenwick, Kerry, Swain, Amanda, Guettler, Sebastian, Lee, Jung-Min, Swisher, Elizabeth M., Stoynov, Stoyno, Yusa, Kosuke, Ashworth, Alan, Lord, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945626/ https://www.ncbi.nlm.nih.gov/pubmed/29748565 http://dx.doi.org/10.1038/s41467-018-03917-2 |
Ejemplares similares
-
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012) -
Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets
por: Krastev, Dragomir B., et al.
Publicado: (2018) -
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity
por: Frankum, Jessica, et al.
Publicado: (2015) -
Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022) -
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
por: Pettitt, Stephen J., et al.
Publicado: (2023)